Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia

• Príomhchruthaitheoirí: Tremblay G (Údar), Dolph M (Údar), Bhor M (Údar), Said Q (Údar), Roy A (Údar), Elliott B (Údar), Briggs A (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Dove Medical Press, 2018-11-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Gabriel Tremblay,1 Mike Dolph,1 Menaka Bhor,2 Qayyim Said,2 Anuja Roy,2 Brian Elliott,3 Andrew Briggs4 1Health Economics, Purple Squirrel Economics, New York, NY, USA; 2Health Economics and Outcomes Research, Novartis Pharmaceuticals, East Hanover, NJ, USA; 3Hematology, No...